• Abitmer Gultom Departemen Obstetri dan Ginekologi
  • Erica Gilda Minawati Simanjuntak Departemen Anestesiologi, Fakultas Kedokteran, Universitas Kristen Indonesia, Jakarta-Indonesia
Keywords: endometriosis, elagolix, second generation GnRH antagonist, pelvic pain


Endometriosis is an inflammatory condition that affects 6-10% of women of reproductive age, and 50% of them are accompanied by chronic pelvic pain. In Indonesia, found 15-25 percent of infertile women are caused by endometriosis. Although surgery has become a way to diagnose and treat endometriosis, treatment is increasingly important to help manage its chronic symptoms. In addition to oral contraceptives, another class of drugs used for the treatment of endometriosis traditionally are Gonadotropin releasing hormone (GnRH) agonists. Elagolix, the second generation GnRH antagonist, has recently been developed. Elagolix can suppress estrogen in a dose-dependent manner. With its nonpeptide structure, Elagolix allows it to be used orally and is a breakthrough in the use of GnRH peptide agonist and antagonist groups. The purpose of writing this work is to inform the efficacy of Elagolix for the treatment of endometriosis. This writing uses an objective, analytical, systematic literature study method with a descriptive exploratory approach. It can be concluded that Elagolix is clinically efficacious in endometriosis-related pain and is ready to be revolutionary in the challenge of pain management related to endometriosis.